Dofferhoff, Anton S M Piscaer, Ianthe Schurgers, Leon J Visser, Margot P J van den Ouweland, Jody M W de Jong, Pim A Gosens, Reinoud Hackeng, Tilman M van Daal, Henny Lux, Petra
...
Published in
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Respiratory failure and thromboembolism are frequent in SARS-CoV-2-infected patients. Vitamin K activates both hepatic coagulation factors and extrahepatic endothelial anticoagulant protein S, required for thrombosis prevention. In times of vitamin K insufficiency, hepatic procoagulant factors are preferentially activated over extrahepat...
Top, Oguz Geisen, Ulrich Decker, Eva L Reski, Ralf
Published in
Frontiers in plant science
The use of plants as production platforms for pharmaceutical proteins has been on the rise for the past two decades. The first marketed plant-made pharmaceutical, taliglucerase alfa against Gaucher's disease produced in carrot cells by Pfizer/Protalix Biotherapeutics, was approved by the US Food and Drug Administration (FDA) in 2012. The advantages...
Soori, Shahrzad Dadashizadeh, Ghazaleh Dorgalaleh, Akbar Tabibian, Shadi Keramati, Mohammad R Alizadeh, Shaban Hosseini, Maryam S Zaker, Farhad Shams, Mahmood
Published in
Cardiovascular & hematological disorders drug targets
About one-fourth of patients with hemophilia A (HA) develop alloantibodies against factor (F) VIII, as the main treatment challenge. Here, we assessed the relationship between interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α), FII and FV polymorphisms and risk of inhibitor formation in patients with severe HA. We divided 39 patients with ...
Zhang, Shulin Taylor, Annette K. Huang, Xuan Luo, Biao Spector, Elaine B. Fang, Ping Richards, C. Sue
Published in
Genetics in Medicine
Factor V Leiden and factor II c.*97G>A (formerly referred to as prothrombin 20210G>A) are the two most common genetic variants associated with venous thromboembolism (VTE). Testing for these variants is one of the most common referrals in clinical genetics laboratories. While the methodologies for testing these two variants are relatively straightf...
Tomaselli, Gordon F Mahaffey, Kenneth W Cuker, Adam Dobesh, Paul P Doherty, John U Eikelboom, John W Florido, Roberta Hucker, William Mehran, Roxana Messé, Steven R
...
Published in
Journal of the American College of Cardiology
Lee, Jeong H Reier, Jason Heffner, Kelley M Barton, Christopher Spencer, David Schmelzer, Albert E Venkat, Raghavan
Published in
Biotechnology and bioengineering
Coagulation factor II (prothrombin; FII) is the pre-proteolyzed precursor to thrombin in the coagulation cascade. It has 10 sites of gamma-carboxylation, which are required for its bioactivity, and is N-glycosylated at three of four putative sites. Production of recombinant human FII (rhFII) using a platform fed-batch process designed for monoclona...
Zantek, Nicole D Morgan, Shanna Zantek, Paul F Mair, David C Bowman, Robert J Aysola, Agnes
Published in
Journal of clinical apheresis
Therapeutic plasma exchange (TPE) without plasma replacement results in coagulation factor removal. Warfarin decreases the activity of vitamin K dependent coagulation factors. The combined effect of TPE and warfarin on the coagulation system has not been studied. A prospective, observational study was conducted in patients undergoing TPE while on w...
Rühl, Heiko Schröder, Lars Müller, Jens Fimmers, Rolf Sukhitashvili, Shorena Welz, Julia Kuhn, Walther C. Oldenburg, Johannes Rudlowski, Christian Pötzsch, Bernd
...
Published in
Thrombosis Research
IntroductionThe estrogen antagonist tamoxifen (TAM) increases the thrombotic risk similar to estrogen containing oral contraceptives (OC). In OC users this risk is attributed to alterations of hemostasis resulting in acquired resistance to activated protein C (APC). TAM-induced APC resistance has not been reported yet. Materials and MethodsBlood sa...
Mierla, Dana Szmal, Camelia Neagos, Daniela Cretu, Ruxandra Stoian, Veronica Jardan, Dumitru
Published in
Maedica
The genes involved in thrombophilia could be one reason for fertility complications in some women with unexplained infertility. Our study shows that there is an association between factor II and V mutation and the risk for fetal loss.
Tempfer, Clemens B Riener, Eva-Katrin Hefler, Lukas A Keck, Christoph
Published in
Personalized medicine
Genetic thrombophilia has been established as a risk factor for pregnancy-associated disorders, such as thrombosis, early and late miscarriage, and pre-eclampsia. Associations between the factor V (F5) Leiden G1691A and the prothrombin/factor II (F2) G20210A SNPs and pre-eclampsia have been evaluated in over 50 association studies. A pooled analysi...
